{
  "fullName": "Nikhil C. Munshi",
  "slug": "nikhil-c-munshi",
  "title": "MD",
  "specialty": "Multiple Myeloma Genomics",
  "geography": {
    "country": "United States",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "UNRANKED",
  "rankingScore": 28,
  "hIndex": 152,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "The Bidhan Chandra Roy Award is an award instituted in 1962 in memory of Bidhan Chandra Roy by the National Medical Commission. It is presented by the President of India in New Delhi every year on July 1, the National Doctors' Day. It is also the highest honour that can be achieved by a doctor in India.",
  "aiSummary": "Nikhil C. Munshi is a multiple myeloma genomics specialist with an H-index of 152 at Harvard University (Faculty). Has been published in Nature, The Lancet Oncology, New England Journal of Medicine. Based in United States.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Harvard University",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Multiple Myeloma Genomics"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Signatures of mutational processes in human cancer",
      "journal": "Nature",
      "year": 2013,
      "citationCount": 9881,
      "doi": "10.1038/nature12477",
      "sourceUrl": "https://doi.org/10.1038/nature12477",
      "verified": true
    },
    {
      "title": "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma",
      "journal": "The Lancet Oncology",
      "year": 2016,
      "citationCount": 2834,
      "doi": "10.1016/s1470-2045(16)30206-6",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(16)30206-6",
      "verified": true
    },
    {
      "title": "Antitumor Activity of Thalidomide in Refractory Multiple Myeloma",
      "journal": "New England Journal of Medicine",
      "year": 1999,
      "citationCount": 2573,
      "doi": "10.1056/nejm199911183412102",
      "sourceUrl": "https://doi.org/10.1056/nejm199911183412102",
      "verified": true
    },
    {
      "title": "Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma",
      "journal": "New England Journal of Medicine",
      "year": 2021,
      "citationCount": 2235,
      "doi": "10.1056/nejmoa2024850",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2024850",
      "verified": true
    },
    {
      "title": "Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells",
      "journal": "Science",
      "year": 2013,
      "citationCount": 1758,
      "doi": "10.1126/science.1244851",
      "sourceUrl": "https://doi.org/10.1126/science.1244851",
      "verified": true
    },
    {
      "title": "Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell Cancer",
      "journal": "New England Journal of Medicine",
      "year": 2001,
      "citationCount": 1726,
      "doi": "10.1056/nejmoa003013",
      "sourceUrl": "https://doi.org/10.1056/nejmoa003013",
      "verified": true
    },
    {
      "title": "Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma",
      "journal": "New England Journal of Medicine",
      "year": 2019,
      "citationCount": 1670,
      "doi": "10.1056/nejmoa1817226",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1817226",
      "verified": true
    },
    {
      "title": "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study",
      "journal": "The Lancet",
      "year": 2021,
      "citationCount": 1529,
      "doi": "10.1016/s0140-6736(21)00933-8",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(21)00933-8",
      "verified": true
    },
    {
      "title": "Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts",
      "journal": "New England Journal of Medicine",
      "year": 2011,
      "citationCount": 1202,
      "doi": "10.1056/nejmoa1103283",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1103283",
      "verified": true
    },
    {
      "title": "Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma",
      "journal": "New England Journal of Medicine",
      "year": 2017,
      "citationCount": 1198,
      "doi": "10.1056/nejmoa1611750",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1611750",
      "verified": true
    },
    {
      "title": "Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1",
      "journal": "Blood",
      "year": 2011,
      "citationCount": 1013,
      "doi": "10.1182/blood-2010-10-299487",
      "sourceUrl": "https://doi.org/10.1182/blood-2010-10-299487",
      "verified": true
    },
    {
      "title": "NF-κB as a Therapeutic Target in Multiple Myeloma",
      "journal": "Journal of Biological Chemistry",
      "year": 2002,
      "citationCount": 891,
      "doi": "10.1074/jbc.m200360200",
      "sourceUrl": "https://doi.org/10.1074/jbc.m200360200",
      "verified": true
    },
    {
      "title": "Heterogeneity of genomic evolution and mutational profiles in multiple myeloma",
      "journal": "Nature Communications",
      "year": 2014,
      "citationCount": 889,
      "doi": "10.1038/ncomms3997",
      "sourceUrl": "https://doi.org/10.1038/ncomms3997",
      "verified": true
    },
    {
      "title": "Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma",
      "journal": "Blood",
      "year": 2010,
      "citationCount": 855,
      "doi": "10.1182/blood-2010-02-268862",
      "sourceUrl": "https://doi.org/10.1182/blood-2010-02-268862",
      "verified": true
    },
    {
      "title": "Molecular sequelae of proteasome inhibition in human multiple myeloma cells",
      "journal": "Proceedings of the National Academy of Sciences",
      "year": 2002,
      "citationCount": 747,
      "doi": "10.1073/pnas.202445099",
      "sourceUrl": "https://doi.org/10.1073/pnas.202445099",
      "verified": true
    },
    {
      "title": "The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications",
      "journal": "Blood",
      "year": 2003,
      "citationCount": 701,
      "doi": "10.1182/blood-2002-06-1768",
      "sourceUrl": "https://doi.org/10.1182/blood-2002-06-1768",
      "verified": true
    },
    {
      "title": "Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications",
      "journal": "Blood",
      "year": 2002,
      "citationCount": 666,
      "doi": "10.1182/blood.v99.12.4525",
      "sourceUrl": "https://doi.org/10.1182/blood.v99.12.4525",
      "verified": true
    },
    {
      "title": "IMWG consensus on risk stratification in multiple myeloma",
      "journal": "Leukemia",
      "year": 2013,
      "citationCount": 592,
      "doi": "10.1038/leu.2013.247",
      "sourceUrl": "https://doi.org/10.1038/leu.2013.247",
      "verified": true
    },
    {
      "title": "A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance",
      "journal": "Cancer Cell",
      "year": 2012,
      "citationCount": 575,
      "doi": "10.1016/j.ccr.2012.08.007",
      "sourceUrl": "https://doi.org/10.1016/j.ccr.2012.08.007",
      "verified": true
    },
    {
      "title": "Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up",
      "journal": "Journal of Clinical Oncology",
      "year": 2022,
      "citationCount": 571,
      "doi": "10.1200/jco.22.00842",
      "sourceUrl": "https://doi.org/10.1200/jco.22.00842",
      "verified": true
    },
    {
      "title": "Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341",
      "journal": "Blood",
      "year": 2003,
      "citationCount": 568,
      "doi": "10.1182/blood-2002-08-2543",
      "sourceUrl": "https://doi.org/10.1182/blood-2002-08-2543",
      "verified": true
    },
    {
      "title": "Graft-versus-myeloma effect: proof of principle",
      "journal": "Blood",
      "year": 1996,
      "citationCount": 551,
      "doi": "10.1182/blood.v87.3.1196.bloodjournal8731196",
      "sourceUrl": "https://doi.org/10.1182/blood.v87.3.1196.bloodjournal8731196",
      "verified": true
    },
    {
      "title": "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients",
      "journal": "Blood",
      "year": 2001,
      "citationCount": 543,
      "doi": "10.1182/blood.v98.2.492",
      "sourceUrl": "https://doi.org/10.1182/blood.v98.2.492",
      "verified": true
    },
    {
      "title": "Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications",
      "journal": "Proceedings of the National Academy of Sciences",
      "year": 2003,
      "citationCount": 527,
      "doi": "10.1073/pnas.2536759100",
      "sourceUrl": "https://doi.org/10.1073/pnas.2536759100",
      "verified": true
    },
    {
      "title": "A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma",
      "journal": "Blood",
      "year": 2006,
      "citationCount": 520,
      "doi": "10.1182/blood-2006-04-015909",
      "sourceUrl": "https://doi.org/10.1182/blood-2006-04-015909",
      "verified": true
    },
    {
      "title": "Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma",
      "journal": "Blood",
      "year": 1999,
      "citationCount": 502,
      "doi": "10.1182/blood.v93.1.55.401k04_55_65",
      "sourceUrl": "https://doi.org/10.1182/blood.v93.1.55.401k04_55_65",
      "verified": true
    },
    {
      "title": "Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma",
      "journal": "JAMA Oncology",
      "year": 2016,
      "citationCount": 497,
      "doi": "10.1001/jamaoncol.2016.3160",
      "sourceUrl": "https://doi.org/10.1001/jamaoncol.2016.3160",
      "verified": true
    },
    {
      "title": "Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer",
      "journal": "eLife",
      "year": 2014,
      "citationCount": 489,
      "doi": "10.7554/elife.02935",
      "sourceUrl": "https://doi.org/10.7554/elife.02935",
      "verified": true
    },
    {
      "title": "Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma",
      "journal": "Blood",
      "year": 1999,
      "citationCount": 476,
      "doi": "10.1182/blood.v93.1.55",
      "sourceUrl": "https://doi.org/10.1182/blood.v93.1.55",
      "verified": true
    },
    {
      "title": "Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma",
      "journal": "Blood",
      "year": 2014,
      "citationCount": 472,
      "doi": "10.1182/blood-2013-10-535088",
      "sourceUrl": "https://doi.org/10.1182/blood-2013-10-535088",
      "verified": true
    },
    {
      "title": "Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu",
      "journal": "Blood",
      "year": 2007,
      "citationCount": 467,
      "doi": "10.1182/blood-2007-08-107292",
      "sourceUrl": "https://doi.org/10.1182/blood-2007-08-107292",
      "verified": true
    },
    {
      "title": "Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications",
      "journal": "Oncogene",
      "year": 2002,
      "citationCount": 460,
      "doi": "10.1038/sj.onc.1205664",
      "sourceUrl": "https://doi.org/10.1038/sj.onc.1205664",
      "verified": true
    },
    {
      "title": "Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.",
      "journal": "PubMed",
      "year": 2002,
      "citationCount": 456,
      "doi": null,
      "sourceUrl": "https://openalex.org/W2148537814",
      "verified": true
    },
    {
      "title": "Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3",
      "journal": "Blood",
      "year": 2011,
      "citationCount": 448,
      "doi": "10.1182/blood-2010-10-299529",
      "sourceUrl": "https://doi.org/10.1182/blood-2010-10-299529",
      "verified": true
    },
    {
      "title": "Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma",
      "journal": "Blood",
      "year": 2012,
      "citationCount": 431,
      "doi": "10.1182/blood-2011-07-366633",
      "sourceUrl": "https://doi.org/10.1182/blood-2011-07-366633",
      "verified": true
    },
    {
      "title": "Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma",
      "journal": "New England Journal of Medicine",
      "year": 2022,
      "citationCount": 426,
      "doi": "10.1056/nejmoa2204925",
      "sourceUrl": "https://doi.org/10.1056/nejmoa2204925",
      "verified": true
    },
    {
      "title": "Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells",
      "journal": "Blood",
      "year": 2006,
      "citationCount": 420,
      "doi": "10.1182/blood-2005-08-3434",
      "sourceUrl": "https://doi.org/10.1182/blood-2005-08-3434",
      "verified": true
    },
    {
      "title": "Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial",
      "journal": "The Lancet Oncology",
      "year": 2014,
      "citationCount": 419,
      "doi": "10.1016/s1470-2045(14)70319-5",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(14)70319-5",
      "verified": true
    },
    {
      "title": "CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy",
      "journal": "Blood",
      "year": 2009,
      "citationCount": 418,
      "doi": "10.1182/blood-2008-10-186668",
      "sourceUrl": "https://doi.org/10.1182/blood-2008-10-186668",
      "verified": true
    },
    {
      "title": "Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma",
      "journal": "Blood",
      "year": 2018,
      "citationCount": 407,
      "doi": "10.1182/blood-2018-06-858613",
      "sourceUrl": "https://doi.org/10.1182/blood-2018-06-858613",
      "verified": true
    },
    {
      "title": "The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis",
      "journal": "Cancer Cell",
      "year": 2007,
      "citationCount": 405,
      "doi": "10.1016/j.ccr.2007.02.015",
      "sourceUrl": "https://doi.org/10.1016/j.ccr.2007.02.015",
      "verified": true
    },
    {
      "title": "MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction",
      "journal": "Blood",
      "year": 2013,
      "citationCount": 405,
      "doi": "10.1182/blood-2012-09-454355",
      "sourceUrl": "https://doi.org/10.1182/blood-2012-09-454355",
      "verified": true
    },
    {
      "title": "Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma",
      "journal": "Blood",
      "year": 2009,
      "citationCount": 395,
      "doi": "10.1182/blood-2008-11-191577",
      "sourceUrl": "https://doi.org/10.1182/blood-2008-11-191577",
      "verified": true
    },
    {
      "title": "International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease",
      "journal": "Blood",
      "year": 2018,
      "citationCount": 391,
      "doi": "10.1182/blood-2018-07-862334",
      "sourceUrl": "https://doi.org/10.1182/blood-2018-07-862334",
      "verified": true
    },
    {
      "title": "Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma",
      "journal": "Nature Communications",
      "year": 2021,
      "citationCount": 385,
      "doi": "10.1038/s41467-021-21177-5",
      "sourceUrl": "https://doi.org/10.1038/s41467-021-21177-5",
      "verified": true
    },
    {
      "title": "A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma",
      "journal": "Blood Advances",
      "year": 2020,
      "citationCount": 383,
      "doi": "10.1182/bloodadvances.2020002827",
      "sourceUrl": "https://doi.org/10.1182/bloodadvances.2020002827",
      "verified": true
    },
    {
      "title": "Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans",
      "journal": "Blood",
      "year": 2013,
      "citationCount": 382,
      "doi": "10.1182/blood-2012-08-448548",
      "sourceUrl": "https://doi.org/10.1182/blood-2012-08-448548",
      "verified": true
    },
    {
      "title": "Biologic sequelae of nuclear factor–κB blockade in multiple myeloma: therapeutic applications",
      "journal": "Blood",
      "year": 2002,
      "citationCount": 367,
      "doi": "10.1182/blood.v99.11.4079",
      "sourceUrl": "https://doi.org/10.1182/blood.v99.11.4079",
      "verified": true
    },
    {
      "title": "Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells",
      "journal": "Blood",
      "year": 2009,
      "citationCount": 364,
      "doi": "10.1182/blood-2009-01-199604",
      "sourceUrl": "https://doi.org/10.1182/blood-2009-01-199604",
      "verified": true
    },
    {
      "title": "International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease",
      "journal": "Journal of Clinical Oncology",
      "year": 2013,
      "citationCount": 352,
      "doi": "10.1200/jco.2012.47.7901",
      "sourceUrl": "https://doi.org/10.1200/jco.2012.47.7901",
      "verified": true
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:23.000Z",
  "openalexId": "https://openalex.org/A5045740077"
}